Ovarian Adenocarcinoma

Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC)

PMID 20942669 · Wiegand et al., 2010 · Open in CIViC

A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC)

PMID 27209210 · Mignogna et al., 2016 · Open in CIViC

One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcri… (full text at CIViC)

PMID 26324360 · Grisham et al., 2015 · Open in CIViC

A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC)

PMID 26490654 · Combe et al., 2015 · Open in CIViC

In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC)

PMID 24882434 · Ledermann et al., 2014 · Open in CIViC

In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC)

PMID 23415752 · Stordal et al., 2013 · Open in CIViC

In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC)

PMID 24882434 · Ledermann et al., 2014 · Open in CIViC

A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors

PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC

High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).

PMID 26625204 · Darb-Esfahani et al., 2016 · Open in CIViC

In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and redu… (full text at CIViC)

PMID 24240700 · Bajrami et al., 2014 · Open in CIViC

Patients with high-grade serous ovarian cancer (HGSOC) and EMSY overexpression (n = 265) received platinum-based first-line chemotherapy. When comparing patients with high and low EMSY expression, usi… (full text at CIViC)

PMID 31154673 · Hollis et al., 2019 · Open in CIViC

Ovarian mucinous carcinoma responds poorly to paclitaxel and carboplatin, prompting interest in targeted therapy, and it resembles gastro-oesophageal adenocarcinoma, a tumour type in which HER2 (ERBB2… (full text at CIViC)

PMID 20003286 · McAlpine et al., 2009 · Open in CIViC

Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT … (full text at CIViC)

PMID 26324360 · Grisham et al., 2015 · Open in CIViC

Ovarian clear cell carcinoma is an aggressive and relatively chemotherapy-resistant form of ovarian cancer with a molecular landscape distinct from that of the more common epithelial subtypes. Earlier… (full text at CIViC)

PMID 19349352 · Kuo et al., 2009 · Open in CIViC

In a retrospective cohort of 16 patients treated with primary debulking surgery followed by platinum-taxane chemotherapy (carboplatin and paclitaxel), patients classified as platinum-resistant exhibit… (full text at CIViC)

PMID 35093146 · Yang et al., 2022 · Open in CIViC